** Shares of Australian Clinical Labs ACL.AX fall 18.9% to A$3, their lowest level since August 30, 2024
** Pathology services provider posts HY underlying NPAT of A$12.1 million ($7.68 million), below Visible Alpha consensus of A$15.5 million
** Co say it's on track to deliver FY25 underlying EBIT guidance in range of A$65 million to A$73 million, mid-point of which is lower than Visible Alpha consensus of A$71 million
** 1.1 million shares change hands, 2.1x the 30-day average of 527,734
** Stock down 12.8% YTD, including session's moves
($1 = 1.5748 Australian dollars)
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。